{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Characterized using descriptive statistics. If differences are noted between pre- and post-treatment protein expression, pairwise comparisons will be made using paired t-test or an equivalent nonparametric test. The normality assumption will be assessed on the log-transformed data prior to paired t-test evaluation.","groups":[{"description":"Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate and MTX. Re-Induction Block 3 patients receive Cytarabine.\n\nL-asparaginase: Given IM 6000 IU/m2/dose Days 2 and 9\n\ndoxorubicin hydrochloride: Given IV 60 mg/m2/dose on Day 1\n\ntherapeutic hydrocortisone: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 \\& 29 Block 2: Days 1 \\& 22\n\nvincristine sulfate: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22\n\ncytarabine: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 \\& 9\n\nprednisone: Given PO or IV 40 mg/m2/day on Days 1-28\n\nbortezomib: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 \\& 11 Block 2: Days 1, 4 \\& 8\n\npegaspargase: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 \\& 22\n\nMTX: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 \\& 29 Block 2: Days 1 \\& 22\n\netopo","id":"OG000","title":"Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs"},{"description":"Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate and MTX. Re-Induction Block 3 patients receive Cytarabine.\n\nL-asparaginase: Given IM 6000 IU/m2/dose Days 2 \\& 9\n\ndoxorubicin hydrochloride: Given IV 60 mg/m2/dose on Day 1\n\ntherapeutic hydrocortisone: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 \\& 29 Block 2: Days 1 \\& 22\n\nvincristine sulfate: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 \\& 22\n\ncytarabine: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 \\& 9\n\nprednisone: Given PO or IV 40 mg/m2/day on Days 1-28\n\nbortezomib: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 \\& 11 Block 2: Days 1, 4 \\& 8\n\npegaspargase: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 \\& 22\n\nMTX: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 \\& 29 Block 2: Days 1 \\& 22\n\netopo","id":"OG001","title":"Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs"},{"description":"Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and MTX. Re-Induction Block 3 patients receive Cytarabine.\n\nL-asparaginase: Given IM 6000 IU/m2/dose Days 2 \\& 9\n\ndoxorubicin hydrochloride: Given IV 60 mg/m2/dose on Day 1\n\ntherapeutic hydrocortisone: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 \\& 29 Block 2: Days 1 \\& 22\n\nvincristine sulfate: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 \\& 22\n\ncytarabine: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 \\& 9\n\nprednisone: Given PO or IV 40 mg/m2/day on Days 1-28\n\nbortezomib: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 \\& 11 Block 2: Days 1, 4 \\& 8\n\npegaspargase: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 \\& 22\n\nMTX: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 \\& 29 Block 2: Days 1 \\& 22\n\netopo","id":"OG002","title":"Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs"},{"description":"Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and MTX. Re-Induction Block 3 patients receive Cytarabine.\n\nL-asparaginase: Given IM 6000 IU/m2/dose Days 2 \\& 9\n\ndoxorubicin hydrochloride: Given IV 60 mg/m2/dose on Day 1\n\ntherapeutic hydrocortisone: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 \\& 29 Block 2: Days 1 \\& 22\n\nvincristine sulfate: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 \\& 22\n\ncytarabine: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 \\& 9\n\nprednisone: Given PO or IV 40 mg/m2/day on Days 1-28\n\nbortezomib: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 \\& 11 Block 2: Days 1, 4 \\& 8\n\npegaspargase: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 \\& 22\n\nmethotrexate: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 \\& 29 Block 2: Days 1 \\& 22\n\netopo","id":"OG003","title":"T-cell ALL (Chemotherapy)"},{"description":"Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and MTX. Re-Induction Block 3 patients receive Cytarabine.\n\nL-asparaginase: Given IM 6000 IU/m2/dose Days 2 \\& 9\n\ndoxorubicin hydrochloride: Given IV 60 mg/m2/dose on Day 1\n\ntherapeutic hydrocortisone: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 \\& 29 Block 2: Days 1 \\& 22\n\nvincristine sulfate: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 \\& 22\n\ncytarabine: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 \\& 9\n\nprednisone: Given PO or IV 40 mg/m2/day on Days 1-28\n\nbortezomib: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 \\& 11 Block 2: Days 1, 4 \\& 8\n\npegaspargase: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 \\& 22\n\nMTX: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 \\& 29 Block 2: Days 1 \\& 22\n\netopo","id":"OG004","title":"T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)"}],"populationDescription":"These were for correlative biology studies and the data were not collected in COG database.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Expression of Apoptotic and Cell Cycle Proteins Assessed by Using Gene and Tissue Microarrays and Immunoblots","type":"OTHER_PRE_SPECIFIED"}